Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Mechanism of Action

Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.

Typical Dosage (Research)

FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.

Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.

Side Effects & Risks

Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.

Contraindicated in patients with active malignancy, hypersensitivity to GHRH, or during pregnancy. May affect glucose metabolism. Requires monitoring of IGF-1 levels.

Who Uses Tesamorelin

HIV patients with lipodystrophy (approved use), individuals seeking fat loss, those interested in GH-related benefits without direct GH administration.